Consider a common sequence. A specialist prescribes a medication and it lands in the EHR. The patient gets to the pharmacy, sees the price, and walks away without filling it. The record now shows an active drug the patient isn’t taking. Nobody knows an alternative is needed — and the patient, embarrassed, says nothing until the next visit months later. The list is wrong in a way that specifically hides a cost problem, and the delay is measured in months of untreated condition.
Here is why the medication list is where affordability becomes visible — or stays hidden — and what the evidence says about the silence.
Cost is the discrepancy the record is worst at seeing
An unaffordable prescription creates a very specific kind of inaccuracy: the drug is prescribed and documented but never filled or taken. The EHR shows it as active; reality diverges silently.
- Abandonment tracks price almost linearly. When a prescription costs under $10, only about 7% of patients abandon it; at $250, abandonment jumps to about 54%; and above $500 per fill it reaches roughly 60% (Tebra / IQVIA 2025; IQVIA abandonment data).
- The volume is large. IQVIA reported patients abandoned 96 million new prescriptions at pharmacies in a single year — about 27% of new prescriptions written (Tebra / IQVIA 2025).
- Cost-related nonadherence is widespread. An estimated 10–30% of adults engage in cost-coping behaviors — not filling, skipping doses, or splitting pills to stretch a prescription (WashU Public Health Sciences).
None of this is visible in an EHR medication list that records what was ordered. Only a check against what the patient actually did — or a direct question to the patient — reveals it.
The silence is the core problem — and it’s well documented
The reason the specialist’s unaffordable prescription sits unaddressed until the next visit is that patients rarely raise cost, and clinicians rarely ask.
- In a national survey of older adults who underused medication because of cost, two-thirds never told a clinician in advance they planned to, and 35% never discussed it at all. Of those who stayed silent, 66% said nobody ever asked about their ability to pay (Piette et al., Arch Intern Med 2004).
- Only 35% of patients experiencing cost-related nonadherence reported ever having a cost discussion with their doctor (AJMC survey).
- In a direct observation of 79 primary care visits, cost conversations occurred in just 37% of visits — and having underlying affordability concerns did not make a conversation more likely (Exploratory Res Clin Soc Pharm, 2023).
- When cost is discussed, patients find it helpful — 72% of those who talked with a clinician about medication cost found the conversation useful (Piette et al. 2004). The barrier is that the conversation rarely happens.
The AAFP has noted the same pattern from the clinician side: high prescription cost is a common cause of nonadherence, but most patients will not mention cost concerns unless specifically asked (AAFP, Fam Pract Manag 2019).
Why the gap delays care specifically
The affordability gap doesn’t just leave a list inaccurate — it delays the clinical correction that would follow if the truth were known.
- If the clinician believes the specialist’s medication is on board, the condition appears treated — so no alternative is offered and no follow-up is triggered until the patient returns and the gap surfaces.
- Meanwhile the patient is untreated for the interval, and the most common cost-coping behaviors — skipping, splitting, not filling — produce exactly the silent therapy interruption the record conceals (WashU).
- Cost-related nonadherence is associated with higher morbidity and mortality, including elevated cardiovascular events — the delay has clinical weight, not just administrative cost (AJMC).
An affordable alternative usually exists. The problem is timing: the clinician can only offer it once they know the first drug was never filled — and today they usually learn that months late, if at all.
A patient-confirmed list surfaces the gap earlier
The affordability picture becomes actionable exactly when the patient confirms what they’re actually taking — because “I never filled that one” is a flag the patient can raise even when they’d never volunteer the word cost.
- Asking beats waiting. Since cost surfaces mostly when someone asks, a pre-visit confirmation that lets the patient mark a medication as “not taking / never started” catches the unfilled specialist prescription before the visit, not after it (Piette et al. 2004).
- Home is where the honest answer lives. Patients confirm most accurately with the bottles in front of them — which is also where the absence of a bottle for an unfilled drug is most obvious (Gionfriddo et al., PLOS One 2021).
- The clinician gets the delta before the appointment. Instead of discovering the gap at the next visit, the care team opens the encounter knowing the specialist’s drug was never started — and can bring an affordable alternative into the same visit.
A patient marking a drug as never-filled doesn’t state the reason, and the reason isn’t always cost. But it converts an invisible discrepancy into a visible prompt — the opening a clinician needs to ask the affordability question the literature says patients are waiting to be asked.
What this does and doesn’t claim
Surfacing an unfilled prescription is not the same as solving affordability — that still takes a cost conversation, a formulary check, and sometimes assistance programs. And no tool guarantees a patient will disclose. The narrow, defensible point is that a wrong list hides the cost gap, and a patient-confirmed list reveals it earlier, where the clinician can act.
ConfirmMyMeds is a working application. It asks the patient to confirm their clinic’s medication list before the appointment — outside the portal, with the bottles in hand — and returns what they confirmed, what they flagged, and what they never started, timestamped and attributed. It never writes to your record; the clinician decides what goes in the chart and what to do about a gap. We have no outcome data and make no claims about adherence or affordability outcomes. We’re looking for clinics to help us learn where it fails.
This article discusses medication affordability in general terms and is not medical or financial advice.